Research
Komen grantee Alex Cheng is working to determine the overall burden on patients of breast cancer treatment so they can better choose what care is right for them and their circumstances.
Maintaining a healthy lifestyle can provide many benefits, including the potential to lower a person’s risk of developing breast cancer.
Komen Researcher Dr. Aileen Fernandez says identifying persons who don’t respond to treatments can be just as important as finding ones who do.
Biosimilars are FDA-approved drugs that are “highly similar” to an existing biologic drug. A common biologic used to treat HER2-positive breast cancer is trastuzumab (Herceptin®). There are several biosimilars to trastuzumab available to treat early and metastatic HER2-positive breast cancers. A few facts about biosimilars: Biosimilars are used to treat breast cancer and also […]
The approval of more treatment options for MBC gives doctors, and patients, more tools and options to use in patient care. Biosimilars are just one example of the additional tools doctors are using with patients.
New medicines and therapies to treat some of the most complicated diseases are available because of years of research and rigorous testing. That process has led to more breast cancer treatment options called biosimilars.
The issue of treatment resistance has confounded researchers for years and is a question that Svasti Haricharan, Ph.D, and her lab are working to better understand.
Dr. Jennifer Rosenbluth specializes in inflammatory breast cancer, an uncommon but deadly subtype of breast cancer.
A look at genetics and history can help us understand who is at greater risk of developing breast cancer so that we can save more lives.
Trainees in Komen’s Training Breast Cancer Researchers to Eliminate Disparities (TREND) program presented work and participated in discussions about improving health equity for breast cancer patients.
Komen-funded research and updates presented at SABCS show there are new treatment options for breast cancers.
Susan G. Komen virtually gathered leading experts and advocates in academia, philanthropy and industry to address breast cancer disparities.
